Literature DB >> 27480860

Tyrphostin AG1478 Inhibits Encephalomyocarditis Virus and Hepatitis C Virus by Targeting Phosphatidylinositol 4-Kinase IIIα.

Cristina M Dorobantu1, Christian Harak2, Rahel Klein2, Lonneke van der Linden3, Jeroen R P M Strating1, Hilde M van der Schaar1, Volker Lohmann2, Frank J M van Kuppeveld4.   

Abstract

Encephalomyocarditis virus (EMCV), like hepatitis C virus (HCV), requires phosphatidylinositol 4-kinase IIIα (PI4KA) for genome replication. Here, we demonstrate that tyrphostin AG1478, a known epidermal growth factor receptor (EGFR) inhibitor, also inhibits PI4KA activity, both in vitro and in cells. AG1478 impaired replication of EMCV and HCV but not that of an EMCV mutant previously shown to escape PI4KA inhibition. This work uncovers novel cellular and antiviral properties of AG1478, a compound previously regarded only as a cancer chemotherapy agent.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27480860      PMCID： PMC5038282          DOI： 10.1128/AAC.01331-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  31 in total

Review 1.  Phosphatidylinositol 4-kinases: Function, structure, and inhibition.

Authors:  Evzen Boura; Radim Nencka
Journal:  Exp Cell Res       Date:  2015-07-14       Impact factor: 3.905

2.  Tyrphostins IV--highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines.

Authors:  A Gazit; J Chen; H App; G McMahon; P Hirth; I Chen; A Levitzki
Journal:  Bioorg Med Chem       Date:  1996-08       Impact factor: 3.641

Review 3.  Tyrosine kinase inhibition: an approach to drug development.

Authors:  A Levitzki; A Gazit
Journal:  Science       Date:  1995-03-24       Impact factor: 47.728

4.  Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication.

Authors:  Jason Borawski; Philip Troke; Xiaoling Puyang; Veronica Gibaja; Shanchaun Zhao; Craig Mickanin; Juliet Leighton-Davies; Christopher J Wilson; Vic Myer; Ivan Cornellataracido; Jeremy Baryza; John Tallarico; Gerard Joberty; Marcus Bantscheff; Markus Schirle; Tewis Bouwmeester; Joanna E Mathy; Kai Lin; Teresa Compton; Mark Labow; Brigitte Wiedmann; L Alex Gaither
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

5.  A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase IIIβ.

Authors:  Hilde M van der Schaar; Pieter Leyssen; Hendrik J Thibaut; Armando de Palma; Lonneke van der Linden; Kjerstin H W Lanke; Céline Lacroix; Erik Verbeken; Katja Conrath; Angus M Macleod; Dale R Mitchell; Nicholas J Palmer; Hervé van de Poël; Martin Andrews; Johan Neyts; Frank J M van Kuppeveld
Journal:  Antimicrob Agents Chemother       Date:  2013-07-29       Impact factor: 5.191

6.  Immunocytochemical techniques reveal multiple, distinct cellular pools of PtdIns4P and PtdIns(4,5)P(2).

Authors:  Gerald R V Hammond; Giampietro Schiavo; Robin F Irvine
Journal:  Biochem J       Date:  2009-07-29       Impact factor: 3.857

7.  A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C.

Authors:  Jan M Vrolijk; Artur Kaul; Bettina E Hansen; Volker Lohmann; Bart L Haagmans; Solko W Schalm; Ralf Bartenschlager
Journal:  J Virol Methods       Date:  2003-06-30       Impact factor: 2.014

8.  Mapping of functional domains of the lipid kinase phosphatidylinositol 4-kinase type III alpha involved in enzymatic activity and hepatitis C virus replication.

Authors:  Christian Harak; Danijela Radujkovic; Cyntia Taveneau; Simon Reiss; Rahel Klein; Stéphane Bressanelli; Volker Lohmann
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

9.  Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target.

Authors:  Frédéric H Vaillancourt; Martine Brault; Louise Pilote; Nathalie Uyttersprot; Elias T Gaillard; James H Stoltz; Brian L Knight; Lynn Pantages; Mary McFarland; Steffen Breitfelder; Tim T Chiu; Louiza Mahrouche; Anne-Marie Faucher; Mireille Cartier; Michael G Cordingley; Richard C Bethell; Huiping Jiang; Peter W White; George Kukolj
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

10.  PtdIns4P synthesis by PI4KIIIα at the plasma membrane and its impact on plasma membrane identity.

Authors:  Fubito Nakatsu; Jeremy M Baskin; Jeeyun Chung; Lukas B Tanner; Guanghou Shui; Sang Yoon Lee; Michelle Pirruccello; Mingming Hao; Nicholas T Ingolia; Markus R Wenk; Pietro De Camilli
Journal:  J Cell Biol       Date:  2012-12-10       Impact factor: 10.539
View more
  7 in total

1.  AG1478 Elicits a Novel Anti-Influenza Function via an EGFR-Independent, GBF1-Dependent Pathway.

Authors:  Xu Zhou; Lingxiang Zhu; Cheryl Bondy; Jun Wang; Qianwen Luo; Yin Chen
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

2.  Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines.

Authors:  Chung-Pu Wu; Sung-Han Hsiao; Megumi Murakami; Ming-Jie Lu; Yan-Qing Li; Chia-Hung Hsieh; Suresh V Ambudkar; Yu-Shan Wu
Journal:  Cancer Lett       Date:  2017-09-08       Impact factor: 8.679

3.  Origins of Enterovirus Replication Organelles Established by Whole-Cell Electron Microscopy.

Authors:  Hilde M van der Schaar; Frank J M van Kuppeveld; Charlotte E Melia; Christopher J Peddie; Anja W M de Jong; Eric J Snijder; Lucy M Collinson; Abraham J Koster; Montserrat Bárcena
Journal:  mBio       Date:  2019-06-11       Impact factor: 7.867

Review 4.  Viral rewiring of cellular lipid metabolism to create membranous replication compartments.

Authors:  Jeroen Rpm Strating; Frank Jm van Kuppeveld
Journal:  Curr Opin Cell Biol       Date:  2017-02-24       Impact factor: 8.382

Review 5.  Targeting host lipid flows: Exploring new antiviral and antibiotic strategies.

Authors:  Alberto Fernández-Oliva; Paula Ortega-González; Cristina Risco
Journal:  Cell Microbiol       Date:  2019-01-17       Impact factor: 3.715

6.  Identification of Repurposable Drugs and Adverse Drug Reactions for Various Courses of COVID-19 Based on Single-Cell RNA Sequencing Data.

Authors:  Zhihan Wang; Kai Guo; Pan Gao; Qinqin Pu; Min Wu; Changlong Li; Junguk Hur
Journal:  ArXiv       Date:  2020-05-16

7.  Repurposable drugs for SARS-CoV-2 and influenza sepsis with scRNA-seq data targeting post-transcription modifications.

Authors:  Zhihan Wang; Kai Guo; Pan Gao; Qinqin Pu; Changlong Li; Junguk Hur; Min Wu
Journal:  Precis Clin Med       Date:  2021-08-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.